Contemporary prostate cancer radiation therapy trials may underestimate the risk of biochemical recurrence
Indexing of testosterone levels to PSA levels in high-level radiotherapy trials using androgen deprivation therapy was uncommon, possibly rendering data on BCR unreliable, potentially underestimating BCR rates.
Authors
- José M. Flores (ORCID: https://orcid.org/0000-0002-8912-7037)
- John P. Mulhall (ORCID: https://orcid.org/0000-0001-5455-3047)
- Michael West
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- The Journal of Sexual Medicine
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1093/jsxmed/qdae191
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Prostate Cancer Foundation
- Patient-Centered Outcomes Research Institute
- Memorial Sloan-Kettering Cancer Center